Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151223 · ClinicalTrials.gov registry record
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
A clinical trial of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT06151223 is a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 5,000 participants, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06151223, a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
- OTHER Bio-specimen Collection: Blood
- OTHER Bio-specimen Collection: Pancreatic Juice
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2031-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06151223
The ClinicalTrials.gov registry entry for NCT06151223 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.
NCT06151223 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06151223 about?
NCT06151223 is a clinical study titled "A Prospective Registry for Patients at High-Risk for Pancreatic Cancer". This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying e...
What is the current status of trial NCT06151223?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-07-13. Estimated completion is 2031-07-31.
What conditions does trial NCT06151223 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.
What interventions are being tested in trial NCT06151223?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Bio-specimen Collection: Blood (OTHER), Bio-specimen Collection: Pancreatic Juice (OTHER).
Who is sponsoring clinical trial NCT06151223?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151223 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.